These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28277102)

  • 1. Immune-related ocular toxicities in solid tumor patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Oweira H; Petrausch U; Helbling D; Schmidt J; Mannhart M; Mehrabi A; Schöb O; Giryes A
    Expert Rev Anticancer Ther; 2017 Apr; 17(4):387-394. PubMed ID: 28277102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune-related neurological toxicities among solid tumor patients treated with immune checkpoint inhibitors: a systematic review.
    Eltobgy M; Oweira H; Petrausch U; Helbling D; Schmidt J; Mehrabi A; Schöb O; Giryes A; Decker M; Abdel-Rahman O
    Expert Rev Neurother; 2017 Jul; 17(7):725-736. PubMed ID: 28548892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment-related Death in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysis.
    Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Oweira H
    Clin Oncol (R Coll Radiol); 2017 Apr; 29(4):218-230. PubMed ID: 27894673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review.
    Abdel-Rahman O; Eltobgy M; Oweira H; Giryes A; Tekbas A; Decker M
    Immunotherapy; 2017 Nov; 9(14):1175-1183. PubMed ID: 29067884
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Risk of hepatotoxicity in cancer patients treated with immune checkpoint inhibitors: A systematic review and meta-analysis of published data.
    Wang W; Lie P; Guo M; He J
    Int J Cancer; 2017 Sep; 141(5):1018-1028. PubMed ID: 28263392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab.
    Passiglia F; Galvano A; Rizzo S; Incorvaia L; Listì A; Bazan V; Russo A
    Int J Cancer; 2018 Mar; 142(6):1277-1284. PubMed ID: 29080213
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; Fouad M
    Ther Adv Respir Dis; 2016 Jun; 10(3):183-93. PubMed ID: 26944362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacovigilance Assessment of Immune-Mediated Reactions Reported for Checkpoint Inhibitor Cancer Immunotherapies.
    Ali AK; Watson DE
    Pharmacotherapy; 2017 Nov; 37(11):1383-1390. PubMed ID: 28950039
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Management of Toxicities of Immune Checkpoint Inhibitors].
    Horio Y
    Gan To Kagaku Ryoho; 2017 Mar; 44(3):185-190. PubMed ID: 28292987
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment-associated Fatigue in Cancer Patients Treated with Immune Checkpoint Inhibitors; a Systematic Review and Meta-analysis.
    Abdel-Rahman O; Helbling D; Schmidt J; Petrausch U; Giryes A; Mehrabi A; Schöb O; Mannhart M; Zidan A; Oweira H
    Clin Oncol (R Coll Radiol); 2016 Oct; 28(10):e127-38. PubMed ID: 27339403
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ocular and orbital side-effects of checkpoint inhibitors: a review article.
    Antoun J; Titah C; Cochereau I
    Curr Opin Oncol; 2016 Jul; 28(4):288-94. PubMed ID: 27136135
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current status and future directions of the immune checkpoint inhibitors ipilimumab, pembrolizumab, and nivolumab in oncology.
    Barbee MS; Ogunniyi A; Horvat TZ; Dang TO
    Ann Pharmacother; 2015 Aug; 49(8):907-37. PubMed ID: 25991832
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Factors associated with ocular adverse event after immune checkpoint inhibitor treatment.
    Kim YJ; Lee JS; Lee J; Lee SC; Kim TI; Byeon SH; Lee CS
    Cancer Immunol Immunother; 2020 Dec; 69(12):2441-2452. PubMed ID: 32556494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of elevated transaminases in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Expert Opin Drug Saf; 2015 Oct; 14(10):1507-18. PubMed ID: 26394770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cutaneous adverse effects of the immune checkpoint inhibitors.
    Collins LK; Chapman MS; Carter JB; Samie FH
    Curr Probl Cancer; 2017; 41(2):125-128. PubMed ID: 28190531
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.
    Nishijima TF; Shachar SS; Nyrop KA; Muss HB
    Oncologist; 2017 Apr; 22(4):470-479. PubMed ID: 28275115
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of gastrointestinal complications in cancer patients treated with immune checkpoint inhibitors: a meta-analysis.
    Abdel-Rahman O; ElHalawani H; Fouad M
    Immunotherapy; 2015; 7(11):1213-27. PubMed ID: 26513491
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of toxicities of immune checkpoint inhibitors.
    Spain L; Diem S; Larkin J
    Cancer Treat Rev; 2016 Mar; 44():51-60. PubMed ID: 26874776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ocular adverse events in PD-1 and PD-L1 inhibitors.
    Young L; Finnigan S; Streicher H; Chen HX; Murray J; Sen HN; Sharon E
    J Immunother Cancer; 2021 Jul; 9(7):. PubMed ID: 34226280
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.